City

Atlanta (1)

Houston (1)

Condition

Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation (2)

Metastatic Urothelial Carcinoma (2)

Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant (1)

Infiltrating Bladder Urothelial Carcinoma With Glandular Differentiation (1)

Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant (1)

Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant (1)

Locally Advanced Urothelial Carcinoma (1)

MTAP Negative (1)

Unresectable Urothelial Carcinoma (1)

Overall Status

Recruiting (2)

Phase

phase 1 (1)

phase 2 (1)

Sponsor

Emory University (1)

M.D. Anderson Cancer Center (1)

Collaborator

National Cancer Institute (NCI) (2)

Exelixis (1)

Intervention

avelumab (1)

cabozantinib s-malate (1)

enfortumab vedotin (1)

pemetrexed (1)

quality-of-life assessment (1)

questionnaire administration (1)

Study Documents

Intervention Type

drug (2)

other (1)

Funder Type

Other (2)

Study Type

Interventional (2)

infiltrating bladder urothelial carcinoma with squamous differentiation

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation, Locally Advanced Urothelial Carcinoma, Metastatic

Recruiting

Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation
+3 more

Cabozantinib S-malate
+3 more

Atlanta, Georgia

Emory University Hospital/Winship Cancer Institute

Aug 8, 2022

Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant, Infiltrating Bladder Urothelial Carcinoma With Glandular

Recruiting

Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant
+6 more

Houston, Texas

M D Anderson Cancer Center

Nov 17, 2021